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Abstract
BACKGROUND—There are conflicting data on the effects of antipsychotic medications on 
delirium in patients in the intensive care unit (ICU).
METHODS—In a randomized, double-blind, placebo-controlled trial, we assigned patients with 
acute respiratory failure or shock and hypoactive or hyperactive delirium to receive intravenous 
boluses of haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg daily), 
or placebo. The volume and dose of a trial drug or placebo was halved or doubled at 12-hour 
intervals on the basis of the presence or absence of delirium, as detected with the use of the 
Confusion Assessment Method for the ICU, and of side effects of the intervention. The primary 
end point was the number of days alive without delirium or coma during the 14-day intervention 
period. Secondary end points included 30-day and 90-day survival, time to freedom from 
mechanical ventilation, and time to ICU and hospital discharge. Safety end points included 
extrapyramidal symptoms and excessive sedation.
RESULTS—Written informed consent was obtained from 1183 patients or their authorized 
representatives. Delirium developed in 566 patients (48%), of whom 89% had hypoactive delirium 
and 11% had hyperactive delirium. Of the 566 patients, 184 were randomly assigned to receive 
placebo, 192 to receive haloperidol, and 190 to receive ziprasidone. The median duration of 
exposure to a trial drug or placebo was 4 days (interquartile range, 3 to 7). The median number of 
days alive without delirium or coma was 8.5 (95% confidence interval [CI], 5.6 to 9.9) in the 
placebo group, 7.9 (95% CI, 4.4 to 9.6) in the haloperidol group, and 8.7 (95% CI, 5.9 to 10.0) in 
the ziprasidone group (P=0.26 for overall effect across trial groups). The use of haloperidol or 
ziprasidone, as compared with placebo, had no significant effect on the primary end point (odds 
ratios, 0.88 [95% CI, 0.64 to 1.21] and 1.04 [95% CI, 0.73 to 1.48], respectively). There were no 
significant between-group differences with respect to the secondary end points or the frequency of 
extrapyramidal symptoms.
CONCLUSIONS—The use of haloperidol or ziprasidone, as compared with placebo, in patients 
with acute respiratory failure or shock and hypoactive or hyperactive delirium in the ICU did not 
significantly alter the duration of delirium. (Funded by the National Institutes of Health and the 
VA Geriatric Research Education and Clinical Center; MIND-USA ClinicalTrials.gov number, 
NCT01211522.)
DELIRIUM IS THE MOST COMMON MANIfestation of acute brain dysfunction during 
critical illness, affecting 50 to 75% of patients who receive mechanical ventilation in an 
intensive care unit (ICU).1,2 Patients with delirium have higher mortality,3-5 longer periods 
of mechanical ventilation and hospital stays,6,7 higher costs,8 and a higher risk of long-term 
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cognitive impairment9-11 than patients who do not have delirium. Delirium also interferes 
with medical care. Hyperactive delirium can lead to unplanned removal of devices,12 
whereas hypoactive delirium prevents participation in nursing interventions, physical 
therapy, and occupational therapy.13
Haloperidol, a typical antipsychotic medication, is often used to treat hyperactive delirium in 
the ICU, and surveys suggest that the drug is also used to treat hypoactive delirium14-17 
despite two small randomized trials that showed no evidence that haloperidol results in a 
shorter duration of delirium in the ICU than placebo.18,19 Atypical antipsychotic 
medications, such as olanzapine, quetiapine, risperidone, and ziprasidone, are also used for 
this purpose, and one placebo-controlled trial has suggested a benefit,20 whereas another18 
showed no evidence of benefit. Therefore, there is conflicting information from small trials, 
meta-analyses, and practice guidelines on the management of delirium in the ICU.1,21
We conducted a multicenter, randomized, double-blind, placebo-controlled trial to examine 
the effects of haloperidol or ziprasidone on delirium during critical illness. We hypothesized 
that typical and atypical antipsychotic medications would result in a shorter duration of 
delirium and coma than placebo and would improve other outcomes.
METHODS
TRIAL DESIGN AND POPULATION
This randomized, double-blind, placebo-controlled, phase 3 trial was conducted at 16 
medical centers in the United States. Before we randomly assigned the patients to receive a 
trial drug or placebo, we obtained written informed consent from the patients or their 
authorized representatives. The institutional review board at each participating center 
approved the protocol, available with the full text of this article at NEJM.org. The Food and 
Drug Administration approved an Investigational New Drug application, which was obtained 
because the intravenous route of administration and the indication for delirium that were 
used in this trial are not approved for antipsychotic medications (see the Supplementary 
Appendix, available at NEJM.org). The trial was registered at ClinicalTrials.gov on 
September 29, 2010, before the first patient was enrolled. The statistical analysis plan was 
registered at Open Science Framework (https://osf.io/mq38r) on March 22, 2018, before the 
trial-group assignments were unmasked. The authors vouch for the accuracy and 
completeness of the data and for the fidelity of the trial to the protocol.
Patients who had been admitted to the participating hospitals were eligible for inclusion if 
they were 18 years of age or older and were receiving treatment in a medical or surgical ICU 
with invasive or noninvasive positive pressure ventilation, vasopressors, or an intraaortic 
balloon pump, and they were eligible for random assignment to a trial group if they had 
delirium. We excluded patients who, at baseline, had severe cognitive impairment, as 
determined by medical record review and the short form of the Informant Questionnaire on 
Cognitive Decline in the Elderly (IQCODE; scores range from 1.0 to 5.0, with higher scores 
indicating more severe cognitive impairment [a score of ≥4.5 resulted in exclusion because 
of severe dementia])22; were at high risk for medication side effects because of pregnancy, 
breast-feeding, a history of torsades de pointes, QT prolongation, a history of neuroleptic 
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malignant syndrome, or allergy to haloperidol or ziprasidone; were receiving ongoing 
treatment with an antipsychotic medication; were in a moribund state; had rapidly resolving 
organ failure; were blind, deaf, or unable to speak or understand English; were incarcerated; 
or were enrolled in another study or trial that prohibited coenrollment. Details of the 
inclusion and exclusion criteria are provided in the Supplementary Appendix. Noncomatose 
patients were excluded if informed consent could not be obtained within 72 hours after 
inclusion criteria had been met, and comatose patients were excluded if informed consent 
could not be obtained within 120 hours after inclusion criteria had been met.
TRIAL-GROUP ASSIGNMENT
To minimize the time between the onset of delirium and randomization, we obtained 
informed consent, when possible, before the onset of delirium; delirium was detected with 
the use of the Confusion Assessment Method for the ICU (CAM-ICU),23,24 a validated tool 
that identifies delirium on the basis of an acute change or fluctuating course of mental status 
plus inattention and either altered level of consciousness or disorganized thinking. If 
delirium was not present at the time that informed consent was obtained, trained research 
personnel evaluated patients twice daily until delirium was present or until death, discharge 
from the ICU, development of an exclusion criterion, or a maximum of 5 days.
When delirium was present at the time of informed consent or during the 5 days after 
informed consent was obtained and the corrected QT interval was less than 550 msec on a 
12-lead electrocardiogram (see the Supplementary Appendix), we randomly assigned the 
patients, in a 1:1:1 ratio, to receive placebo, haloperidol, or ziprasidone using a computer-
generated, permuted-block randomization scheme, with stratification according to trial site. 
The research personnel, managing clinicians, patients, and their families were not aware of 
the trial-group assignments.
The trial drugs or placebo were administered intravenously with the use of colorless 
preparations delivered in identical bags. Immediately after the trial-group assignment, the 
first dose of a trial drug or placebo was administered: patients younger than 70 years of age 
received 0.5 ml of placebo (0.9% saline) or 2.5 mg of haloperidol per 0.5 ml or 5 mg of 
ziprasidone per 0.5 ml, whereas those who were 70 years of age or older received 0.25 ml of 
placebo or 1.25 mg of haloperidol per 0.25 ml or 2.5 mg of ziprasidone per 0.25 ml. 
Subsequent doses were administered every 12 hours at approximately 10 a.m. and 10 p.m. 
Research personnel doubled the volume and dose of the trial drug or placebo if a patient had 
delirium, was not yet receiving the maximum dose, and had not met criteria that required the 
trial drug or placebo to be withheld. Patients in the haloperidol group received a dose of up 
to 10 mg per administration and up to 20 mg per day, and those in the ziprasidone group 
received a dose of up to 20 mg per administration and up to 40 mg per day.
We halved the volume and dose of a trial drug or placebo if a patient did not have delirium 
(i.e., had a negative CAM-ICU assessment) for two consecutive assessments and was not yet 
receiving the minimum dose. We temporarily withheld a trial drug or placebo if a patient did 
not have delirium for four consecutive assessments or for safety reasons. We permanently 
discontinued a trial drug or placebo when any of the following occurred: torsades de pointes, 
neuroleptic malignant syndrome, drug reaction with eosinophilia and systemic symptoms 
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syndrome, new-onset coma due to structural brain disease, or any life-threatening, serious 
adverse event that was related to the intervention, as determined by an independent data and 
safety monitoring board. We discontinued a trial drug or placebo after the 14-day 
intervention period or at ICU discharge, whichever occurred first.
To evaluate the efficacy and to guide volume and dose adjustments of trial drug or placebo, 
patients were assessed twice daily while they were receiving the intervention by trained 
research personnel using the CAM-ICU23,24 and the Richmond Agitation–Sedation Scale 
(RASS),25,26 a validated, 10-level scale that rates the level of consciousness from 
unresponsive to physical stimuli (score of −5) to combative (score of +4). We considered any 
day during which at least one CAM-ICU assessment was positive to be a day with delirium; 
a positive assessment was considered to indicate hyperactive delirium if the RASS score was 
higher than 0 and hypoactive delirium if the RASS score was 0 or lower.27
During the period when the patients were receiving a trial drug or placebo and for 4 days 
after discontinuation, we assessed the patients for side effects. Twice a day, before each 
administration of the intervention, we assessed the patients for a corrected QT prolongation 
of 550 msec using telemetry and, if telemetry indicated a corrected QT prolongation of 550 
msec, we used 12-lead electrocardiography. Once daily, we assessed extrapyramidal 
symptoms using a modified Simpson–Angus Scale, a 5-item scale on which each item is 
scored from 0 to 4, with higher scores indicating worse extrapyramidal symptoms28; 
akathisia using a 10-point visual-analogue scale; and dystonia using a standardized 
definition.18
Treating clinicians were educated about the “ABCDE” treatment bundle (assess, prevent, 
and manage pain; both spontaneous awakening and breathing trials; choice of analgesia and 
sedation; assess, prevent, and manage delirium; and early mobility and exercise) and were 
encouraged to perform the treatment bundle to mitigate delirium among the patients in the 
ICU.29-33 Throughout the trial, we monitored its use and recorded adherence to each 
component of the bundle daily among the patients for whom informed consent was obtained.
END POINTS
The primary end point was days alive without delirium or coma (defined as the number of 
days that a patient was alive and free from both delirium and coma during the 14-day 
intervention period). Secondary efficacy end points included duration of delirium, time to 
freedom from mechanical ventilation (defined as extubation that was followed by at least a 
48-hour period during which the patient was alive and free from mechanical ventilation), 
time to final successful ICU discharge (defined as the last ICU discharge during the index 
hospitalization that was followed by at least a 48-hour period during which the patient was 
alive and outside the ICU), time to ICU readmission, time to successful hospital discharge 
(defined as discharge that was followed by at least a 48-hour period during which the patient 
was alive and outside the hospital), and 30-day and 90-day survival. Safety end points 
included the incidence of torsades de pointes and neuroleptic malignant syndrome and the 
severity of extrapyramidal symptoms, as measured on the modified Simpson–Angus Scale.
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STATISTICAL ANALYSIS
Descriptions of sample-size calculations and statistical methods are included in the 
Supplementary Appendix. We sought to randomly assign 561 patients (187 per trial group), 
which would provide the trial with at least 80% power to detect a 2-day difference between 
groups in days alive without delirium or coma, at a twosided significance level of 2.5% 
(after Bonferroni adjustment for two pairwise comparisons).
We analyzed all data using an intention-to-treat approach and compared the effects of 
haloperidol, ziprasidone, and placebo with respect to the primary end point using the 
Kruskal–Wallis test in unadjusted analyses and proportional-odds logistic regression in 
adjusted analyses. The primary analysis was performed with the use of an adjusted 
proportional-odds logistic-regression model that examined the effects of an intervention on 
days alive without delirium or coma, with a two-sided significance level of 2.5% to account 
for two pairwise comparisons, which were to be analyzed only if the P value for the overall 
effect across trial groups was significant. There was no plan for adjustment for multiple 
comparisons of secondary end points, and those results are reported without P values as 
point estimates with 95% confidence intervals that have not been adjusted for multiple 
comparisons. A total of 300 of 6100 (5%) potential assessments for delirium or coma were 
missing; we imputed these individual assessments using polytomous logistic regression that 
included multiple covariates. After calculating days alive without delirium or coma, we then 
used complete case analysis for all outcomes (see the Supplementary Appendix). We 
collected and managed data using REDCap electronic data-capture tools and used R 
software, version 3.4.4,34 for data management and statistical analyses. R code is available 
through Open Science Framework (https://osf.io/mq38r).
RESULTS
PATIENTS
From December 2011 through August 2017, we screened 20,914 patients, of whom 16,306 
(78%) met one or more exclusion criteria (Fig. 1). Of the remaining 4608 patients, 3425 
(74%) patients or their authorized representatives declined to participate, and 1183 (26%) 
consented to be assessed further to determine whether they met eligibility criteria. Among 
those, 46 (4%) met exclusion criteria, and 571 (48%) never had delirium before ICU 
discharge, leaving 566 patients (48%) who had delirium and met the criteria for random 
assignment to a trial group. At the time of randomization, 89% of the patients had 
hypoactive delirium, and 11% had hyperactive delirium. There were no significant 
differences in baseline characteristics between the trial groups (Table 1).
INTERVENTIONS AND CONCURRENT SEDATING MEDICATIONS
The duration and number of doses of a trial drug or placebo received by the patients during 
the 14-day intervention period were similar in the three groups (Table S1 in the 
Supplementary Appendix). All but two patients received at least one dose of a trial drug or 
placebo. The median duration of exposure to a trial drug or placebo was 4 days (interquartile 
range, 3 to 7), and the mean (±SD) daily doses of haloperidol and ziprasidone administered 
were 11.0±4.8 mg and 20.0±9.4 mg, respectively.
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Approximately half the patients had a trial drug or placebo temporarily withheld at least 
once during the trial (Table S2 in the Supplementary Appendix); the frequency of 
withholding an intervention did not differ significantly between the trial groups. A trial drug 
or placebo was permanently discontinued at a similar frequency and for similar reasons in 
the three trial groups.
A total of 118 patients (21%) received an open-label antipsychotic medication during the 
trial; the frequency of use and doses administered were similar in the three trial groups 
(Table S1 in the Supplementary Appendix). The median cumulative dose of a nontrial, open-
label antipsychotic medication in haloperidol equivalents was 5 mg (interquartile range, 2 to 
12) over a median of 2 days (interquartile range, 1 to 5). Approximately 90% of patients 
received one or more doses of analgesics or sedatives, and the duration of exposure to these 
agents was similar in the three trial groups (Table S3 in the Supplementary Appendix). The 
daily rate of adherence to each of the five components of the ABCDE bundle was greater 
than 88% in all three trial groups (see the Supplementary Appendix).
EFFICACY END POINTS
The adjusted median number of days alive without delirium or coma was 8.5 (95% CI, 5.6 to 
9.9) in the placebo group, as compared with 7.9 (95% CI, 4.4 to 9.6) in the haloperidol 
group and 8.7 (95% CI, 5.9 to 10.0) in the ziprasidone group (Fig. 2). The P value for the 
overall effect across trial groups was 0.26, and therefore, as prespecified in the protocol, no 
P values were calculated for pairwise comparisons. In adjusted and unadjusted analyses of 
the active trial-drug groups, as compared with the placebo group, the 95% confidence 
intervals for the odds ratios included unity for days with delirium and for days with coma 
during the 14-day intervention period (Fig. 2 and Table 2). In analyses of 30-day and 90-day 
survival as well as time to freedom from mechanical ventilation, ICU discharge, ICU 
readmission, and hospital discharge, the 95% confidence intervals for the hazard ratios of the 
effects of haloperidol and ziprasidone, as compared with placebo, included unity (Table 2 
and Fig. 3; and see the Supplementary Appendix).
The results regarding the heterogeneity of effect across interventions are available in the 
Supplementary Appendix. The effects of antipsychotic medications on durations of delirium, 
coma, and hypoactive delirium, as well as on 90-day survival, differed according to age, but 
the trial may not have been adequately powered to draw conclusions about these subgroups. 
There were no significant interactions between the severity of illness at randomization and 
the effects of antipsychotic medications on outcomes of mental status.
SAFETY END POINTS
The frequency of excessive sedation, the most common safety end point, did not differ 
significantly between the trial groups (Table S2 in the Supplementary Appendix). 
Prolongation of the corrected QT interval was more common in the ziprasidone group than 
in the haloperidol group or placebo group. Torsades de pointes developed in two patients in 
the haloperidol group during the intervention period, but neither patient had received 
haloperidol during the 4 days immediately preceding the arrhythmia. One patient in the 
haloperidol group had the trial drug withheld because of suspected neuroleptic malignant 
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syndrome, but this diagnosis was subsequently ruled out. Three patients (one in each group) 
had a trial drug or placebo withheld because of extrapyramidal symptoms, and one patient in 
the haloperidol group had the trial drug withheld specifically because of dystonia.
DISCUSSION
For more than 40 years, intravenous antipsychotic medications have been used to treat 
delirium in hospitalized patients.16,35-39 In an international survey of 1521 intensivists, 65% 
reported that they treat delirium in the ICU with haloperidol and 53% reported that they treat 
delirium with atypical antipsychotic medications.16 In this double-blind, randomized, 
placebo-controlled trial of intravenous antipsychotic medications for the treatment of 
delirium in the ICU, there was no evidence that either haloperidol or ziprasidone led to a 
shorter duration of delirium and coma. Patients who received treatment with up to 20 mg of 
haloperidol per day or up to 40 mg of ziprasidone per day and those who received placebo 
had similar outcomes, including survival and lengths of stay in the ICU and hospital.
The results of our trial were similar to those of two earlier placebo-controlled trials that 
examined haloperidol for delirium in smaller numbers of patients in the ICU. In the 
Modifying the Incidence of Delirium (MIND) trial,18 101 patients receiving mechanical 
ventilation in the ICU were randomly assigned to receive enteral haloperidol, ziprasidone, or 
placebo; the results showed no significant differences in days alive without delirium or 
coma. In the Haloperidol Effectiveness in ICU Delirium (Hope-ICU) trial,19 142 patients 
receiving mechanical ventilation in the ICU were randomly assigned to receive intravenous 
haloperidol or placebo; the results also showed no effect on days alive without delirium or 
coma, although there were fewer days with agitated delirium in patients who received 
haloperidol.
One possible reason that we found no evidence that the use of haloperidol or ziprasidone 
resulted in a fewer days with delirium or coma than placebo is that the mechanism of brain 
dysfunction that is considered to be targeted by antipsychotic medications — increased 
dopamine signaling — may not play a major role in the pathogenesis of delirium during 
critical illness. Another possible reason is that heterogeneous mechanisms may be 
responsible for delirium in critically ill patients. Sedation with γ-aminobutyric acid agonists, 
for example, is a common risk factor for delirium during critical illness.40 In the current 
trial, approximately 90% of the patients received one or more doses of sedatives or 
analgesics, and the doses of sedatives and off-trial antipsychotic medications and the 
durations of exposures to those agents were similar in all trial groups. Most patients in the 
trial had hypoactive delirium, which made it difficult to estimate the effect of antipsychotic 
medications on hyperactive delirium. Nevertheless, the delirium-assessment tool that was 
used to determine the trial outcomes takes into account integrated aspects of the delirium 
syndrome and supports the conclusion that the trial drugs had no effect on the duration of 
delirium as compared with placebo.
Strengths of this trial include a large sample size, broad inclusion criteria to enhance 
generalizability, delivery of the trial drug or placebo in a double-blinded fashion, and use of 
validated instruments administered by trained personnel. Limitations of this investigation 
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should also be considered. The possibility of an effect size of less than a 2-day difference in 
days alive without delirium or coma cannot be excluded, because the trial was powered to 
detect a 2-day difference between groups with respect to the primary end point. We studied 
two specific antipsychotic medications, and our results do not exclude the possibility that 
other antipsychotic medications could reduce the duration of delirium.20 We did not limit 
our enrollment to a homogeneous group of patients who had delirium in the ICU, and our 
findings allow for the possibility that some patients (e.g., nonintubated patients with 
hyperactive delirium describing delusions and hallucinations, those with alcohol withdrawal, 
or those with another delirium phenotype2) may benefit from antipsychotic treatment. The 
20-mg dose of haloperidol that we used in the trial is considered to be high,36-38 and yet we 
cannot exclude a potential benefit from higher doses.39 In keeping with the literature on 
haloperidol use,41 which indicates that a dose of haloperidol higher than 25 mg per day has a 
deleterious effect on cognition, we chose a dose that would avoid these adverse effects. 
Finally, although this trial was powered to detect clinically meaningful between-group 
differences with respect to the primary end point, it lacked sufficient power to assess 
whether haloperidol and ziprasidone would significantly increase the risk of infrequent 
complications such as torsades de pointes.42
In conclusion, in this large, double-blind, randomized, placebo-controlled trial, we found no 
evidence that the use of haloperidol (up to 20 mg daily) or ziprasidone (up 40 mg daily) had 
an effect on the duration of delirium among patients with acute respiratory failure or shock 
in the ICU.
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Figure 1. Screening, Randomization, Follow-up, and Analysis.
The numbers of patients excluded for each criterion sum to more than the total excluded 
because some patients met more than one exclusion criterion. ICU denotes intensive care 
unit.
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Figure 2. Effects of Haloperidol, Ziprasidone, and Placebo on Days Alive without Delirium or 
Coma, Days with Delirium, and Days with Coma.
In analyses that were adjusted for age, preexisting cognitive impairment, Clinical Frailty 
Score and Charlson Comorbidity Index score at baseline, and modified Sequential Organ 
Failure Assessment score and Richmond Agitation–Sedation Scale score at randomization, 
there were no significant differences between the trial groups with respect to the primary end 
point (days alive without delirium or coma) and with respect to the secondary end points of 
mental status (durations of delirium and coma).
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Figure 3. Effects of Haloperidol, Ziprasidone, and Placebo on 90-Day Survival.
Shown are Kaplan–Meier curves of the probability of survival. In analyses that were 
adjusted for age, preexisting cognitive impairment, Clinical Frailty Score and Charlson 
Comorbidity Index score at baseline, and modified Sequential Organ Failure Assessment 
score and Richmond Agitation–Sedation Scale score at randomization, there were no 
significant differences in 90-day survival between the trial groups. Results have not been 
adjusted for multiple comparisons. The shading indicates the 95% confidence intervals.
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. o
f d
ay
s (
IQ
R)
4 
(2–
8)
4 
(2–
7)
4 
(2–
6)
 
A
dju
ste
d o
dd
s r
ati
o (
95
% 
CI
)
R
ef
er
en
ce
1.
12
 (0
.86
–1
.46
)
1.
02
 (0
.69
–1
.51
)
D
ay
s w
ith
 h
yp
er
ac
tiv
e 
de
lir
iu
m
 
U
na
dju
ste
d m
ed
ian
 no
. o
f d
ay
s (
IQ
R)
0 
(0–
1)
0 
(0–
1)
0 
(0–
1)
 
A
dju
ste
d o
dd
s r
ati
o (
95
% 
CI
)
R
ef
er
en
ce
1.
18
 (0
.86
–1
.61
)
1.
09
 (0
.70
–1
.70
)
D
ay
s w
ith
 h
yp
oa
ct
iv
e 
de
lir
iu
m
 
U
na
dju
ste
d m
ed
ian
 no
. o
f d
ay
s (
IQ
R)
3 
(2–
8)
4 
(2–
6)
3 
(2–
6)
 
A
dju
ste
d o
dd
s r
ati
o
R
ef
er
en
ce
1.
10
 (0
.81
–1
.48
)
1.
00
 (0
.68
–1
.47
)
D
ay
s w
ith
 c
om
a
 
U
na
dju
ste
d m
ed
ian
 no
. o
f d
ay
s (
IQ
R)
1 
(0–
2)
1 
(0–
2)
1 
(0–
3)
 
A
dju
ste
d o
dd
s r
ati
o (
95
% 
CI
)
R
ef
er
en
ce
1.
01
 (0
.74
–1
.39
)
1.
11
 (0
.77
–1
.61
)
D
ay
s t
o 
fre
ed
om
 fr
om
 m
ec
ha
ni
ca
l v
en
til
at
io
n
 
U
na
dju
ste
d m
ed
ian
 no
. o
f d
ay
s (
IQ
R)
3 
(1–
5)
2 
(1–
6)
3 
(2–
5)
 
A
dju
ste
d h
aza
rd 
rat
io 
(95
% 
CI
)
R
ef
er
en
ce
0.
92
 (0
.71
–1
.19
)
0.
96
 (0
.74
–1
.25
)
D
ay
s t
o 
IC
U
 d
isc
ha
rg
e
 
U
na
dju
ste
d m
ed
ian
 no
. o
f d
ay
s (
IQ
R)
5 
(3–
14
)
5 
(3–
13
)
6 
(3–
10
)
 
A
dju
ste
d h
aza
rd 
rat
io 
(95
% 
CI
)
R
ef
er
en
ce
0.
95
 (0
.81
–1
.12
)
1.
02
 (0
.88
–1
.17
)
IC
U
 re
ad
m
iss
io
n
 
U
na
dju
ste
d n
o. 
of 
pa
tie
nts
 (%
)
23
 (1
2)
27
 (1
4)
18
 (9
)
 
A
dju
ste
d h
aza
rd 
rat
io 
(95
% 
CI
)
R
ef
er
en
ce
1.
13
 (0
.62
–2
.09
)
0.
73
 (0
.49
–1
.10
)
D
ay
s t
o 
ho
sp
ita
l d
isc
ha
rg
e
 
U
na
dju
ste
d m
ed
ian
 no
. o
f d
ay
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R)
13
 (8
–2
3)
13
 (8
–2
2)
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 (8
–2
1)
 
A
dju
ste
d h
aza
rd 
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io
R
ef
er
en
ce
1.
03
 (0
.85
–1
.23
)
1.
05
 (0
.88
–1
.25
)
D
ea
th
 a
t 3
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da
ys
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En
d 
Po
in
t
Pl
ac
eb
o
(N
 = 
18
4)
H
al
op
er
id
ol
(N
 = 
19
2)
Zi
pr
as
id
on
e
(N
 = 
19
0)
 
U
na
dju
ste
d n
o. 
of 
pa
tie
nts
 (%
)
50
 (2
7)
50
 (2
6)
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 (2
8)
 
A
dju
ste
d h
aza
rd 
rat
io 
(95
% 
CI
)
R
ef
er
en
ce
1.
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 (0
.73
–1
.46
)
1.
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 (0
.77
–1
.47
)
D
ea
th
 a
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0 
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ys
 
U
na
dju
ste
d n
o. 
of 
pa
tie
nts
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)
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 (3
4)
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 (3
8)
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 (3
4)
 
A
dju
ste
d h
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rd 
rat
io 
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% 
CI
)
R
ef
er
en
ce
1.
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 (0
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–1
.40
)
1.
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 (0
.79
–1
.30
)
*
Th
e 
P 
va
lu
e 
fo
r t
he
 o
v
er
al
l e
ffe
ct
 a
cr
os
s g
ro
up
s w
as
 0
.2
6;
 th
er
ef
or
e, 
no
 p
ai
rw
ise
 P
 v
al
ue
s w
er
e 
ca
lc
ul
at
ed
. A
ll 
tim
e-
to
-e
v
en
t r
es
ul
ts 
ar
e 
re
po
rte
d 
fo
r t
he
 p
at
ie
nt
s w
ho
 h
ad
 th
e 
ou
tc
om
e 
of
 in
te
re
st.
 R
es
ul
ts 
w
er
e 
n
o
t a
dju
ste
d f
or 
mu
ltip
le 
co
mp
ari
son
s o
f s
eco
nd
ary
 en
d p
oin
ts 
bu
t w
er
e 
ad
jus
ted
 fo
r a
ge
, b
ase
lin
e C
ha
rls
on
 C
om
orb
idi
ty 
Ind
ex
 s
co
re
, 
ba
se
lin
e 
Cl
in
ic
al
 F
ra
ilt
y 
Sc
or
e,
 b
as
el
in
e 
co
gn
iti
v
e 
im
pa
irm
en
t (
as 
de
te
rm
in
ed
 a
cc
or
di
ng
 to
 th
e 
sh
or
t f
or
m
 o
f t
he
 IQ
CO
DE
), m
od
ifi
ed
 S
O
FA
 sc
or
e 
at
 ra
nd
om
iz
at
io
n,
 a
nd
 R
ic
hm
on
d 
A
gi
ta
tio
n–
Se
da
tio
n 
Sc
al
e 
sc
or
e 
at
 ra
nd
om
iz
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io
n.
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